Triple negative breast cancer and ovarian cancer cells were treated with Azacitidine, Talazoparib, or combination for a period of 10 days to assess global transcriptional response. The focus of these
MDA-MB-231 cells were used to determine genes differentially regulated by riluzole, a drug currently used to treat ALS patients The triple-negative breast cancer cell line, MDA-MB-231, was treated ove
A DNA microarray study was conducted to determine the impact of Mt-CFX on mRNA expression and pathway activation in human triple negative breast cancer cells. We used microarrays to detail the global
